200 related articles for article (PubMed ID: 21982869)
1. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2011 Dec; 49(6):1351-6. PubMed ID: 21982869
[TBL] [Abstract][Full Text] [Related]
2. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2014 Aug; 65():1-8. PubMed ID: 24784023
[TBL] [Abstract][Full Text] [Related]
3. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
4. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys.
Stroup GB; Kumar S; Jerome CP
Calcif Tissue Int; 2009 Oct; 85(4):344-55. PubMed ID: 19763376
[TBL] [Abstract][Full Text] [Related]
5. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
6. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
7. Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys.
Yamada H; Ochi Y; Mori H; Nishikawa S; Hashimoto Y; Nakanishi Y; Tanaka M; Bruce M; Deacon S; Kawabata K
Bone; 2016 May; 86():43-52. PubMed ID: 26921823
[TBL] [Abstract][Full Text] [Related]
8. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Eastell R; Dijk DJ; Small M; Greenwood A; Sharpe J; Yamada H; Yuba M; Tanimoto M; Deacon S
Osteoporos Int; 2016 Jan; 27(1):309-18. PubMed ID: 26446770
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study.
Eastell R; Nagase S; Ohyama M; Small M; Sawyer J; Boonen S; Spector T; Kuwayama T; Deacon S
J Bone Miner Res; 2011 Jun; 26(6):1303-12. PubMed ID: 21312264
[TBL] [Abstract][Full Text] [Related]
10. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
11. Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo.
Fujii T; Ishikawa M; Kubo A; Tanaka Y
Bone; 2015 Dec; 81():427-434. PubMed ID: 26297834
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
Nagase S; Ohyama M; Hashimoto Y; Small M; Kuwayama T; Deacon S
J Clin Pharmacol; 2012 Mar; 52(3):306-18. PubMed ID: 21719717
[TBL] [Abstract][Full Text] [Related]
13. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
[TBL] [Abstract][Full Text] [Related]
14. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
15. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
Svelander L; Erlandsson-Harris H; Astner L; Grabowska U; Klareskog L; Lindstrom E; Hewitt E
Eur J Pharmacol; 2009 Jun; 613(1-3):155-62. PubMed ID: 19358841
[TBL] [Abstract][Full Text] [Related]
17. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
[TBL] [Abstract][Full Text] [Related]
18. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.
Nagase S; Hashimoto Y; Small M; Ohyama M; Kuwayama T; Deacon S
Br J Clin Pharmacol; 2012 Dec; 74(6):959-70. PubMed ID: 22533981
[TBL] [Abstract][Full Text] [Related]
19. [New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334].
Manako J
Clin Calcium; 2011 Jan; 21(1):64-9. PubMed ID: 21187596
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats.
Ochi Y; Yamada H; Mori H; Kawada N; Tanaka M; Imagawa A; Ohmoto K; Kawabata K
J Bone Miner Metab; 2016 Jan; 34(1):33-40. PubMed ID: 25762435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
